The Racing Medication and Testing Consortium released the following warning via racing media on May 19:
Mofebutazone is an analogue of phenylbutazone exhibiting a non-steroidal anti-inflammatory (NSAID) mechanism of action. Mofebutazone does not have FDA approval for use in any species.
In its Feb. 20 meeting, the Racing Medication and Testing Consortium's (RMTC) Board of Directors approved a recommendation from its Scientific Advisory Committee (SAC) to designate a 4/B classification for the substance Mofebutazone. Subsequently, the Association of Racing Commissioners International (ARCI) has approved and assigned a 4/B classification to this substance in its Uniform Classification of Foreign Substances, consistent with other NSAIDs lacking FDA approval.
The FDA has advised the RMTC regarding other non-FDA approved drugs that possession is not permitted, nor is the compounding of a non-FDA approved substances.
It is considered a Banned Substance on the FEI Prohibited Substance List. As it lacks FDA approval, it would be classified as a Banned (S0) Substance by HISA's Anti-Doping and Medication Control (ADMC) regulations, recently approved by the Federal Trade Commission.
The post Possession Not Permitted: RMTC Issues Advisory On Mofebutazone Use appeared first on Horse Racing News | Paulick Report.
